Our study investigated the use of ovarian suppression plus adjuvant endocrine therapy on survival outcome in BRCA mutation carriers with hormone receptor positive early breast cancer. The results showed an improvement in progression-free survival in patients using ovarian suppression plus adjuvant endocrine therapy with an adjusted odds ratio of 0.79 and a p-value of 0...
Our study investigated the use of ovarian suppression plus adjuvant endocrine therapy on survival outcome in BRCA mutation carriers with hormone receptor positive early breast cancer. The results showed an improvement in progression-free survival in patients using ovarian suppression plus adjuvant endocrine therapy with an adjusted odds ratio of 0.79 and a p-value of 0.009. So, the use of ovarian suppression improved the progression-free survival compared to endocrine therapy alone. Moreover, in terms of overall survival, similar results. The combination of ovarian suppression plus adjuvant endocrine therapy showed a statistically significant improvement in overall survival compared to endocrine therapy alone, with an adjusted ratio of 0.66, and the p-value was statistically significant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
